HCW Biologics is progressing toward filing an IND application in the first half of 2027 for HCW11-018b, its lead T-Cell Engager candidate designed to treat solid tumors. This second-generation therapy combines a bispecific T-Cell Engager with components that reduce tumor immunosuppression and enhance immune cell activation and infiltration, addressing limitations of existing treatments. The FDA provided clear guidance during a recent meeting, supporting the company's clinical trial plans. Successful IND submission will enable first-in-human studies, potentially advancing treatment options for difficult-to-treat solid tumors.
HCW Biologics' progress toward an IND application for its lead T-Cell Engager therapy provides context for health sector activity on Pluang. For readers following health stocks, as of Oct 09, 2026 18:51 WIB, out of 128 priced US health-sector stocks, 71 rose and 49 fell. Notable movers include TWST at USD 154.45 with a 1-day change of +1.58% and typical hold time of 27 days, CRSP at USD 51.15 up 1.41% with a 77-day hold time, and HIMS at USD 28.45 rising 1.39% with a 21-day hold time and strong buy interest (86% buy orders).
At Malaysia's IGEM 2026, Sigenergy showcased its latest AI-driven energy technologies, including smart storage and inverter systems, highlighting its role in advancing sustainable energy. The company also signed MOUs with local partners Milieu and YT...
A vote on Cardano proposes reducing the fixed minimum stake pool fee from 170 ADA to 75 ADA to help small pools remain viable amid declining block rewards. As of October 10, 2026, approval stands at 34.45% against a required 67%, with the vote closin...
Worldcoin (WLD) surged 9.32% in just four hours to $0.5701 on October 10, extending its 24-hour gain to 14.73%. The price rose from $0.5215 earlier that day, reflecting strong buying interest. During the same period, liquidations related to WLD total...
Bitcoin faces pressure as long-term U.S. Treasury yields hit two-decade highs, rising above 5.3% for 10-year and 5.7% for 30-year bonds. This increase makes government bonds more attractive compared to non-yielding assets like Bitcoin, especially as ...
NEAR Protocol traded at $4.93 on October 10, 2026, rising 8.6% after a sharp 16.37% drop the day before. Despite a 97.5% gain over 30 days, the price has been volatile and flat over the past two weeks, fluctuating within a narrow range. This volatili...
